The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

A phase 1/2 study to evaluate the safety, tolerability, and preliminary efficacy of GP-2250 in combination with gemcitabine for advanced or metastatic pancreatic adenocarcinoma.

Anup  Kasi

Honoraria - OncLive

Research Funding - Astellas Pharma (Inst); Bavarian Nordic (Inst); Cardiff Oncology (Inst); FibroGen (Inst); Geistlich Pharma (Inst); Halozyme (Inst); Novocure (Inst); Rafael Pharmaceuticals (Inst); TESARO (Inst)

Travel, Accommodations, Expenses - Halozyme; Rafael Pharmaceuticals

Jose Luis  Iglesias

Consulting or Advisory Role - Aucentra Therapeutics (Inst); Carina (Inst); Epsilogen (Inst); Geistlich Pharma (Inst); HiberCell (Inst); Senti Biosciences (Inst)